The DOI matches its Crossref record; 9 of the 10 references it cites were found in a registry or an index.
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Open accessAbstract
BACKGROUNDSodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes.More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction. METHODSIn this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy.The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure. RESULTSDuring a median of 16 months, a primary outcome event occurred in 361 of 1863 patients (19.4%) in the empagliflozin group and in 462 of 1867 patients (24.7%) in the placebo group (hazard ratio for cardiovascular death or hospitalization for heart failure, 0.75; 95% confidence interval [CI], 0.65 to 0.86; P<0.001).The effect of empagliflozin on the primary outcome was consistent in patients regardless of the presence or absence of diabetes.The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.70; 95% CI, 0.58 to 0.85; P<0.001).The annual rate of decline in the estimated glomerular filtration rate was slower in the empagliflozin group than in the placebo group (-0.55 vs. -2.28ml per minute per 1.73 m 2 of body-surface area per year, P<0.001), and empagliflozin-treated patients had a lower risk of serious renal outcomes.Uncomplicated genital tract infection was reported more frequently with empagliflozin. CONCLUSIONSAmong patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes.(Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Reduced ClinicalTrials.govnumber, NCT03057977.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Subgroup analyses from DAPA-CKD (117) and analyses from the EMPEROR heart failure trials suggest that SGLT2 inhibitors are safe and effective at eGFR levels of >20 mL/min/1.73m 2 .”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Direct evidence is provided by the DAPA-CKD, SCORED, EMPEROR-Reduced, and EMPEROR-Preserved trials, which enrolled such participants by design.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [101]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, notably, SGLT2i have been studied among patients without T2D who have CKD in the DAPA-CKD trial (and the soonto-be-published EMPA-KIDNEY trial) or who have heart failure (in the DAPA-HF, EMPEROR-Reduced, and EMPEROR-Preserved trials) and did not confer any increased risk of severe hypoglycemia or diabetic ketoacidosis among individuals without T2D.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [101]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“enrollment criteria included eGFR >60 mL/min/1.73m 2 , but efficacy was seen at eGFR >20 mL/min/1.73m 2 in people with heart failure.”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [135]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SGLT2 inhibitors reduce the incidence of heart failure and improve heart failurerelated outcomes, including hospitalization for heart failure and heart failure-related symptoms, in people with diabetes with preserved or reduced ejection fraction (250,(255)(256)(257)(298)(299)(300)(301)(302)(303)(304)(305)(306).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [303]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and the Empagliflozin Outcome Trial in Patients With Chronic Heart Failure (EMPEROR) trials (which provided clear evidence of efficacy and safety for empagliflozin among patients with eGFR ≥20 mL/min/1.73 m2 and HF) (54,57,58).”
From Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022) · cites this paper as [58]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce the risk of hospitalizations for heart failure in 8 large-scale trials, including those that focused on type 2 diabetes, heart failure with a reduced ejection fraction, and chronic kidney disease.1–8”
From Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial (2021) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Over a median follow-up of 16 months, those in the empagli fl ozin-treated group had a reduced risk of the primary outcome (HR 0.75 [95% CI 0.65 -0.86]; P < 0.001) and fewer total hospitalizations for heart failure (HR 0.70 [95% CI 0.58 -0.85]; P < 0.001).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [200]
The cited source says what the claim attributes to it.
In the citing paper
“Clinical trials, such as EMPEROR-REDUCED (empagliflozin) and DAPA-CKD (dapagliflozin), have shown that SGLT-2 inhibitors have benefits in patients with heart failure and chronic kidney disease, regardless of the presence of diabetes.38,39”
From Tirzepatide: Clinical review of the twincretin injectable (2023) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“The primary outcome among those with an eGFR $ 60 ml/min per 1.73 m 2 was HR: 0.67; 95% CI: 0.55 -0.83 and for those with eGFR < 60 ml/min per 1.73 m 2 was HR: 0.83; 95% CI: 0.69 -1.00.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [101]
The cited source says what the claim attributes to it.
In the citing paper
“As seen in DAPA-HF, the primary outcome was similarly reduced for individuals with and without diabetes.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [101]
The cited source says what the claim attributes to it.
In the citing paper
“the primary outcome of cardiovascular death or heart failure hospitalization occurred in 19.4% of the empagli fl ozin group and 24.7% of the placebo group (HR: 0.75; 95% CI: 0.65 -0.86).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [101]
The cited source says what the claim attributes to it.
In the citing paper
“A composite kidney outcome HR of 0.50 (95% CI: 0.32 -0.77) was also reported.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [101]
The cited source says what the claim attributes to it.
In the citing paper
“Similar results were obtained in clinical trials with empagliflozin (303).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [303]
The cited source says what the claim attributes to it.
In the citing paper
“Similar results were obtained in clinical trials with empagliflozin (291).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [291]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The EMPEROR-Reduced 101 and EMPEROR-Preserved 102 trials, although not an exclusive CKD population, did allow enrollment of patients with an eGFR as low as 20 ml/min per 1.73 m 2.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [101]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The EMPA-REG trial enrolled over 7000 patients with T2D, baseline glycated hemoglobin (HbA1c) of 7% -10%, established CVD (almost 100%), and an eGFR of at least 30 ml/min per 1.73 m 2 . 101”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [101]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The EMPEROR-Reduced and EMPEROR-Preserved trials, although not exclusive CKD populations, did allow enrollment participants with an eGFR as low as 20 ml/min per 1.73 m 2 .”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [101]
Experimental — accuracy not yet measuredIn the citing paper
“The EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction) trial demonstrated a benefit of SGLT2 inhibition with empagliflozin to reduce both the risk and rate of heart failure hospitalizations.7”
From Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial (2021) · cites this paper as [7]
In the citing paper
“As previously reported,7 the 2 groups comprised patients with mild, moderate, and severe heart failure, as reflected by left ventricular ejection fraction and circulating levels of NT-proBNP, and were well-balanced with respect to baseline characteristics.”
From Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial (2021) · cites this paper as [7]
In the citing paper
“In the EMPEROR-Reduced trial, empagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure, a benefit that was driven primarily by an effect of the drug to reduce first and recurrent admissions for worsening heart failure.7”
From Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial (2021) · cites this paper as [7]
In the citing paper
“In our original publication and in a meta-analysis of the DAPA-HF and EMPEROR-Reduced trials, we noted a somewhat lesser benefit in patients with ejection fraction of 31% to 40% and in patients with class III symptoms.”
From Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial (2021) · cites this paper as [7]
In the citing paper
“Rates of worsening heart failure or cardiovascular death are lower among patients with heart failure who are treated with dapagliflozin and empagliflozin regardless of diabetes diagnosis.7,8”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [8]
In the citing paper
“As for the morbidity, renal outcome and HHF, it was clear that SGLT-2i had more significant impact than finerenone, which might be explained by the special potency of SGLT-2i such as reducing blood glucose, reducing oxidative stress, losing weight, reducing uric acid, controlling blood pressure and improving renal ultrafiltration and hypoxia [65, 71–79].”
In the citing paper
“Multiple SGLT2i trials included subsets of participants without diabetes, who appear to have derived similar benefits as those with T2D, 8,14,18”
In the citing paper
“Treatment with empagliflozin improved quality of life.496”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [496]
In the citing paper
“The risk of a prespeci fi ed renal composite outcome (chronic dialysis, renal transplantation, or a sustained reduction in eGFR) was lower in the empagli fl ozin group than in the placebo group (1.6% in the empaglifl ozin group vs. 3.1% in the placebo group; HR 0.50 [95% CI 0.32 -0.77]).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [200]
In the citing paper
“Over a median follow-up of 16 months, those in the empagli fl ozin-treated group had a reduced risk of the primary outcome (HR 0.75 [95% CI 0.65 -0.86]; P < 0.001) and fewer total hospitalizations for heart failure (HR 0.70 [95% CI 0.58 -0.85]; P < 0.001).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [200]
In the citing paper
“The effect of empagli fl ozin on the primary outcome was consistent irrespective of diabetes diagnosis at baseline.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [200]
In the citing paper
“Moreover, in the recent EMPEROR-Reduced trial (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure and a Reduced Ejection Fraction), SGLT2 inhibition did reduce renal events significantly, although that trial used a different renal composite outcome and had more renal events than in DAPA-HF (88 versus 67).”
From Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF (2021) · cites this paper as [21]
In the citing paper
“More recently, in a large trial using empagliflozin in patients with HFrEF, the rate of decline in eGFR was 2.28 (SD 0.23) mL·min–1·1.73 m–2 per year, which was reduced to 0.55 (0.23) in the SGLT2 inhibitor group.21”
From Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF (2021) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus
Kato, E. T., Silverman, M. G., Mosenzon, O., Zelniker, T. A., Cahn, A., Furtado, R. H. M., Kuder, J., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.040130 · Cited by 557
FITCHETT, D. H., Inzucchi, S. E., Cannon, C. P., McGuire, D. K., Scirica, B. M., Johansen, O. E., Sambevski, S., Kaspers, S., Pfarr, E., George, J. T., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037778 · Cited by 360
Furtado, R. H. M., Bonaca, M. P., Raz, I., Zelniker, T. A., Mosenzon, O., Cahn, A., Kuder, J., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.039996 · Cited by 342
Packer, M. (2020) · Diabetes Care · doi:10.2337/dci19-0074 · Cited by 247
Self-citationDonnan, J. R., Grandy, C. A., Chibrikov, E., Marra, C. A., Aubrey-Bassler, K., Johnston, K., Swab, M., Hache, J., Curnew, D., Nguyen, H., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-022577 · Cited by 222
Natriuretic Peptides as Inclusion Criteria in Clinical Trials
Ibrahim, N. E., Burnett, J. C. J., Butler, J., Camacho, A., Felker, G. M., Fiuzat, M., O’Connor, C. J., Solomon, S. D., Vaduganathan, M., Zile, M. R., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2019.12.010 · Cited by 83
Self-citation
Research works printed but not linked: 1
- 10.1002/ejhf.1536 · DOI
Cited by
Sorted by citations
Items 401–500 of 1,012
Mechanisms and Models in Heart Failure
Mann, D. L., & Felker, G. M. (2021) · Circulation Research · doi:10.1161/circresaha.121.318158 · Cited by 68
Heart Failure Subtypes and Cardiomyopathies in Women
DeFilippis, E. M., Beale, A., Martyn, T., Agarwal, A., Elkayam, U., Lam, C. S. P., & Hsich, E. (2022) · Circulation Research · doi:10.1161/circresaha.121.319900 · Cited by 69
Accelerated lysine metabolism conveys kidney protection in salt-sensitive hypertension
Rinschen, M. M., Palygin, O., El‐Meanawy, A., Domingo-Almenara, X., Palermo, A., Dissanayake, L. V., Golosova, D., Schafroth, M. A., Guijas, C., Demir, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31670-0 · Cited by 65
Mitochondrial dysfunction in heart failure and its therapeutic implications
Liu, M., Lv, J., Pan, Z., Wang, D., Zhao, L., & Guo, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.945142 · Cited by 75
Leccisotti, L., Cinti, F., Sorice, G. P., D’Amario, D., Lorusso, M., Guzzardi, M. A., Mezza, T., Gugliandolo, S., Cocchi, C., Capece, U., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01607-4 · Cited by 69
Aldafas, R., Crabtree, T. S. J., Alkharaiji, M. A., Vinogradova, Y., & IDRIS, I. R. (2023) · Age and Ageing · doi:10.1093/ageing/afad254 · Cited by 73
Teerlink, J. R., Díaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I. S., Arias‐Mendoza, A., Biering‐Sørensen, T., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2015 · Cited by 66
Self-citationSex-Specific Differences in Heart Failure: Pathophysiology, Risk Factors, Management, and Outcomes
Sullivan, K., Doumouras, B. S., Santema, B. T., Walsh, M. N., Douglas, P. S., Voors, A. A., & Spall, H. G. C. V. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.12.025 · Cited by 65
Li, N., Lv, D., Zhu, X., Wei, P., Gui, Y., Liu, S., Zhou, E., Zheng, M., Zhou, D. F., & Zhang, L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.728089 · Cited by 70
“Among them, four (8, 9, 17, 18) included patients with type 2 diabetes, two (11, 19) included patients with diabetic kidney disease, two (7, 20) included patients with heart failure, and three (10, 11, 19) included patients with CKD.”
BackgroundPark, C. H., Lee, B., Han, M., Rhee, W. J., Kwak, M. S., Yoo, T., & Shin, J. (2022) · Cell Death Discovery · doi:10.1038/s41420-021-00801-9 · Cited by 68
Nanomaterials‐assisted metabolic analysis toward in vitro diagnostics
Yang, J., Huang, L., & Qian, K. (2022) · Exploration · doi:10.1002/exp.20210222 · Cited by 65
Mark, P. B., Sarafidis, P. A., Ekart, R., Ferro, C. J., Balafa, O. C., Fernández‐Fernández, B., Herrington, W. G., Rossignol, P., Vecchio, L. D., Valdivielso, J. M., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad112 · Cited by 76
“…With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR Reduced) trial of 3730 people with HFrEF empagliflozin with or without diabetes, empagliflozin reduced risk of the primary composite outcome of cardiovascular death or hospitalization for worsening HF compared to placebo [ 50 ].”
BackgroundOmar, M., Jensen, J., Kistorp, C., Højlund, K., Videbæk, L. M., Tuxen, C., Larsen, J. H., Andersen, C. F., Gustafsson, F., Køber, L., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01463-2 · Cited by 67
Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure
Faridi, K. F., Dayoub, E. J., Ross, J. S., Dhruva, S. S., Ahmad, T., & Desai, N. R. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.04.031 · Cited by 66
Treatment of chronic kidney disease in older populations
Kishi, S., Kadoya, H., & Kashihara, N. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00854-w · Cited by 69
Jhund, P. S., Ponikowski, P. P., Docherty, K. F., Gasparyan, S. B., Böhm, M., Chiang, C., Desai, A. S., Howlett, J. G., Kitakaze, M., Petrie, M. C., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053659 · Cited by 71
Self-citationHerrington, W. G., Savarese, G., Haynes, R., Marx, N., Mellbin, L., Lund, L. H., Dendale, P., Seferovic, P. M., Rosano, G. M. C., Staplin, N., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2286 · Cited by 66
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment
Cherney, D. Z. I., Ferrannini, E., Umpierrez, G. E., Peters, A. L., Rosenstock, J., Carroll, A. K., Lapuerta, P., Banks, P. L., & Agarwal, R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14513 · Cited by 65
Ketone bodies for the failing heart: fuels that can fix the engine?
Yurista, S. R., Nguyen, C. T., Rosenzweig, A., de Boer, R. A., & Westenbrink, B. D. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.07.006 · Cited by 70
Nikolaou, P., Mylonas, N., Makridakis, M., Makrecka‐Kuka, M., Iliou, A., Zerikiotis, S., Efentakis, P., Kampoukos, S., Kostomitsopoulos, N. G., Vilšķe̅rsts, R., et al. (2022) · Basic Research in Cardiology · doi:10.1007/s00395-022-00934-7 · Cited by 64
Diabetic Cardiomyopathy: A Brief Summary on Lipid Toxicity
Ke, J., Pan, J., Lin, H., & Gu, J. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14224 · Cited by 69
“For HFrEF, both the DAPA-HF trial and the EMPEROR-Reduced trial reported lower cardiovascular death by taking SGLT2 inhibitors.(124,125)”
MethodThe NO-cGMP-PKG Axis in HFpEF: From Pathological Mechanisms to Potential Therapies
Cai, Z., Wu, C., Xu, Y., Cai, J., Zhao, M., & Zu, L. (2022) · Aging and Disease · doi:10.14336/ad.2022.0523 · Cited by 69
“studies demonstrated that SGLT2is improved the clinical outcome of patients with HFrEF and that their cardiovascular protective effect was independent of glycaemic control [113, 117-119].”
Result2023 Guidelines on the management of patients with diabetes - a position of Diabetes Poland
Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Borys, S., Budzynski, A. Z., Cyganek, K., Cypryk, K., Czech, A., Czupryniak, L., Drzewoski, J., Dzida, G. J., et al. (2023) · Current Topics in Diabetes · doi:10.5114/ctd/160061 · Cited by 72
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
“40,119,120,124 HF clinical practice guidelines for device-based recommendations should be followed for patients with HFrEF.”
Self-citationCurrent and emerging drug targets in heart failure treatment
Ghionzoli, N., Gentile, F., Franco, A. D., Castiglione, V., Aimo, A., Giannoni, A., Burchielli, S., Cameli, M., Emdin, M., & Vergaro, G. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10137-2 · Cited by 67
Diabetes Mellitus and Heart Failure
Triposkiadis, F. K., Xanthopoulos, A. V., Bargiota, Α., Kitai, T., Katsiki, N., Farmakis, D. T., Skoularigis, J. S., Starling, R. C., & Iliodromitis, E. K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163682 · Cited by 73
Wang, C.-C., Li, Y., Qian, X.-Q., Zhao, H., Wang, D., Zuo, G.-X., & Wang, K. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2064479 · Cited by 67
“Intriguingly, empagliflozin lowers the risk of death of heart failure in non-diabetic patients [35].”
BackgroundKetones: the double-edged sword of SGLT2 inhibitors?
Lupsa, B. C., Kibbey, R. G., & Inzucchi, S. E. (2022) · Diabetologia · doi:10.1007/s00125-022-05815-1 · Cited by 68
“Subsequently, these benefits were also proven in populations with HF (including both those with and without diabetes) in large, randomised clinical trials such as the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPAHF) [9, 13], EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure w…”
BackgroundMechanistic insights of soluble uric acid-induced insulin resistance: Insulin signaling and beyond
Yu, W., Xie, D., Yamamoto, T., Koyama, H., & Cheng, J. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09787-4 · Cited by 64
Koizumi, T., Watanabe, M., Yokota, T., Tsuda, M., Handa, H., Koya, J., Nishino, K., Tatsuta, D., Natsui, H., Kadosaka, T., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1005408 · Cited by 65
“In addition, the cardioprotective benefits of SGLT2-i have also been demonstrated in non-diabetic patients (44, 45).”
BackgroundCOHEN, L. P., Isaza, N., Hernandez, I., Lewis, G. D., Ho, J. E., Fonarow, G. C., Kazi, D. S., & Bellows, B. K. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.0077 · Cited by 72
Mutruc, V., Bologa, C., Șorodoc, V., Ceasovschih, A., Morărașu, B. C., Șorodoc, L., Catar, O., & Lionte, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082833 · Cited by 81
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 101
Bonora, B. M., Raschi, E., Avogaro, A., & Fadini, G. P. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01243-4 · Cited by 66
“In two trials performed on patients with HF and reduced ejection fraction (HFrEF), 42–50% of whom had T2D, SGLT2i significantly improved HF outcomes [3, 4].”
BackgroundMehta, P. B., Robinson, A., Burkhardt, D., & Rushakoff, R. J. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.06.006 · Cited by 64
Chronic kidney disease in patients with diabetes mellitus
Nordheim, E., & Jenssen, T. G. (2021) · Endocrine Connections · doi:10.1530/ec-21-0097 · Cited by 74
Translation of New and Emerging Therapies for Genetic Cardiomyopathies
Helms, A. S., Thompson, A. D., & Day, S. M. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.07.012 · Cited by 68
“Recent trials of inhibitors of sodium-glucose cotransporter-2 have unexpectedly shown additive benefit in patients, independent of the presence of diabetes (20-22).”
BackgroundSenni, M., López-Sendón, J., Solal, A. C., Ponikowski, P. P., Nkulikiyinka, R., Freitas, C., Vlajnic, V., Roessig, L., & Pieske, B. M. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14050 · Cited by 62
“Consistent with the hypothesis that patients with very advanced disease are unable to benefit from pharmacotherapy, clinical trials with other HF therapies have shown that patients in NYHA Class IV are less likely to benefit from treatment.(16,20) The VICTOR study (NCT05093933) will further examine the efficacy and sa…”
ResultSelf-citationMalgie, J., Clephas, P. R. D., Rocca, H. B., de Boer, R. A., & Brugts, J. J. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10325-2 · Cited by 76
“Likewise, the treatment effects of SGLT2i in both DAPA-HF and EMPEROR-reduced were comparable, whether or not patients were on ARNi background therapy [1, 2, 32].”
BackgroundInfluentialOrtíz, A., Ferro, C. J., Balafa, O. C., Burnier, M., Ekart, R., Halimi, J., Kreutz, R. H., Mark, P. B., Persu, A., Rossignol, P., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab167 · Cited by 64
Kahkoska, A. R., Abrahamsen, T. J., Alexander, G. C., Bennett, T. D., Chute, C. G., Haendel, M. A., Klein, K. R., Mehta, H. B., Miller, J. D., Moffitt, R. A., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0065 · Cited by 62
“Two classes of antihyperglycemic medications, glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium–glucose cotransporter 2 inhibitors (SGLT2i), have been associated with a reduction of cardiorenal events and mortality in large trials of cardiovascular outcomes (5–8), heart failure (9,10), and renal outcomes…”
BackgroundImproving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials
DeFilippis, E. M., Echols, M. R., Adamson, P. B., Batchelor, W., Cooper, L. B., Cooper, L. S., Desvigne-Nickens, P. M., George, R. T., Ibrahim, N. E., Jessup, M. L., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.0161 · Cited by 60
Chiang, C., Chiang, C.-H., Chiang, C., Sheng‐Kai, K., Peng, C.-Y., Hsia, Y. P., Horng, C., Chen, C.-Y., Chang, Y.-C., See, X. Y., et al. (2022) · Heart · doi:10.1136/heartjnl-2022-321545 · Cited by 63
Oates, C. P., Santos‐Gallego, C. G., Smith, A., Basyal, B., Moss, N., Kawamura, I., Musikantow, D. R., Turagam, M. K., Miller, M. A., Whang, W., et al. (2023) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.15894 · Cited by 63
“03% of patients in DAPA‐HF, with SCD accounting for 38% and 47% of all‐cause death in these trials.(1,2) Moreover, follow‐up in EMPEROR‐reduced and DAPA‐HF was limited to only 16 and 18 months, respectively.”
BackgroundGuideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition)
Guo, L., & Xiao, X. (2024) · Aging Medicine · doi:10.1002/agm2.12294 · Cited by 69
Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure
Pietschner, R., Kolwelter, J., Bosch, A., Striepe, K., Jung, S., Kannenkeril, D., Ott, C., Schiffer, M., Achenbach, S. S., & Schmieder, R. E. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01410-7 · Cited by 61
Agarwal, R., Anker, S. D., Filippatos, G. S., Pitt, B., Rossing, P. R., Ruilope, L. M., Boletis, J., Toto, R., Umpierrez, G. E., Wanner, C., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab336 · Cited by 61
Self-citationKolwelter, J., Kannenkeril, D., Linz, P. R., Jung, S., Nagel, A. M., Bosch, A., Ott, C., Bramlage, P., Nöh, L., Schiffer, M., et al. (2022) · Clinical Research in Cardiology · doi:10.1007/s00392-022-02119-7 · Cited by 61
Nassif, M. E., Windsor, S. L., GOSCH, K. L., Borlaug, B. A., Husain, M., Inzucchi, S. E., Kitzman, D. W., McGuire, D. K., Pitt, B., Scirica, B. M., et al. (2023) · Circulation Heart Failure · doi:10.1161/circheartfailure.122.009837 · Cited by 61
Riley, D. R. J., Essa, H., Austin, P. J., Preston, F., Kargbo, I., Hernández, G., Ghuman, R., Cuthbertson, D. J., Lip, G. Y. H., & Alam, U. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15185 · Cited by 61
Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies
Chong, K., Chang, J. K.-J., & Chuang, L. (2024) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12800 · Cited by 74
“13,14 The EMPEROR-Preserved Trial shows that empagliflozin is the first SGLT2i agent that reduces the composite risk of cardiovascular death or hospitalization due to heart failure for patients with a preserved ejection fraction (HFpEF), regardless of whether they have diabetes.”
BackgroundMcMurray, J. J. V., Docherty, K. F., de Boer, R. A., Hammarstedt, A., Kitzman, D. W., Kosiborod, M. N., Maria Langkilde, A., Reicher, B., Senni, M., Shah, S. J., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.065061 · Cited by 60
Self-citationWhere the Action Is—Leukocyte Recruitment in Atherosclerosis
Mauersberger, C., Hinterdobler, J., Schunkert, H., Kessler, T., & Sager, H. B. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.813984 · Cited by 67
“Also some anti-hyperglycaemic agents have shown to exert beneficial effects on cardiovascular outcomes, both in diabetic and non-diabetic patients with heart failure (390, 391).”
BackgroundLee, S.-G., Kim, D., Lee, J.-J., Lee, H., Moon, R.-K., Lee, Y., Lee, S., Lee, O., Kim, C., Oh, J., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02485-z · Cited by 59
“Both DAPA-HF (The Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure) and the EMPEROPR Reduced trial (The Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction) showed signi…”
BackgroundSelf-citationPazan, F., Weiß, C., Wehling, M., Members, F. E. P., Wieczorowska–Tobis, K., Kostka, T., Klich‐Rączka, A., Bień, B., Broncel, M., Mierzejewski, P., et al. (2023) · Drugs & Aging · doi:10.1007/s40266-023-01024-6 · Cited by 63
“For instance, the evidence for the evaluation of SGLT2 inhibitors for the treatment of heart failure originates from large RCTs including many older adults, in which the overall benefit of using dapagliflozin [31] or empagliflozin [29] in older Table 3 Items with an original FORTA class that was different from the new…”
BackgroundErtugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial
Kang, D., Park, S., Shin, S., Hwang, I., Yoon, Y. E., Kim, H., Kim, M., Kim, M., Yun, S., Song, J., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069144 · Cited by 59
“Because the clinical benefits of SGLT2 inhibitors were evident in patients with HFrEF (LVEF 35% to 40%), 27,28 and current guidelines recommend SGLT2 inhibitors as a class I indication for HFrEF, 3 our placebo-controlled trial did not include patients with an LVEF 35%.”
BackgroundRanjit Unnikrishnan, I., Shaw, J. E., Chan, J. C. N., Wild, S. H., Peters, A. L., Orrange, S., Roden, M., & Mohan, V. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00635-0 · Cited by 69
“Post-hoc analyses of RCTs that assessed the organ-protective effects of SGLT2 inhibitors (such as dapagliflozin and empagliflozin) in individuals with heart failure or CKD suggested that these drugs might prevent new-onset T2DM, although results were inconsistent 168–170 .”
Lugner, M., Sattar, N. A., Miftaraj, M., Ekelund, J., Franzén, S., Svensson, A., & Eliasson, B. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01258-x · Cited by 60
“Recent evidence also shows benefits on progression of HF when treating patients with existing HF at baseline [17, 18].”
BackgroundSelf-citationKanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W. W. S., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013650.pub2 · Cited by 80
Delanaye, P., & Scheen, A. J. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101285 · Cited by 64
SGLT2 Inhibitors: The Sweet Success for Kidneys
Dharia, A., Khan, A. A., Sridhar, V. S., & Cherney, D. Z. I. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-102135 · Cited by 62
Kwon, O., Myong, J., Lee, Y., Choi, Y.-J., Yi, J. E., Seo, S. M., Jang, S.-W., Kim, P. J., & Lee, J. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.027824 · Cited by 58
Lee, S. A., & Riella, L. V. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.02.1435 · Cited by 65
Lam, C. S. P., Ferreira, J. P., Pfarr, E., Sim, D., Tsutsui, H., Anker, S. D., Butler, J., Filippatos, G. S., Pocock, S., Sattar, N. A., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab360 · Cited by 57
“12%).(5,6) In a meta-analysis of two trials of sodium–glucose co-transporter 2 (SGLT2) inhibitors in HF and a reduced ejection fraction, the regional and race/ethnicity-related heterogeneity was still apparent.”
BackgroundMethodSelf-citationKitakata, H., Endo, J., Hashimoto, S., Mizuno, E., Moriyama, H., Shirakawa, K., Goto, S., Katsumata, Y., Fukuda, K., & Sano, M. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.07.090 · Cited by 57
Mitochondria as Therapeutic Targets in Heart Failure
Schwemmlein, J., Maack, C., & Bertero, E. (2022) · Current Heart Failure Reports · doi:10.1007/s11897-022-00539-0 · Cited by 59
Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure
Zou, X., Shi, Q., Vandvik, P. O., Guyatt, G. H., Lang, C. C., Parpia, S., Wang, S., Agarwal, A., Zhou, Y., Zhu, Y., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m21-4284 · Cited by 60
“All included trials reported all-cause death, 7 reported hospitalization (13– 15, 31–34), and 2 reported kidney failure (13, 15).”
BackgroundInfluentialImpact of Geroscience on Therapeutic Strategies for Older Adults With Cardiovascular Disease
Forman, D. E., Kuchel, G. A., Newman, J. C., Kirkland, J. L., Volpi, E., Taffet, G. E., Barzilai, N., Pandey, A., Kitzman, D. W., Libby, P., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.05.038 · Cited by 64
Biegus, J., Fudim, M., Salah, H. M., Heerspink, H. J. L., Voors, A. A., & Ponikowski, P. P. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2967 · Cited by 57
Self-citationAnabolic androgenic steroids and cardiomyopathy: an update
Fadah, K., Gopi, G., Lingireddy, A., Blumer, V. L., DeWald, T. A., & Mentz, R. J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1214374 · Cited by 68
“Additionally, Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF) (74) and Empagliflozin Outcome Trial in Patients With Chronic Heart Failure and a Reduced Ejection Fraction (EMPEROR-Reduced) trial (75) demonstrated a decrease in hospitalization and all-cause mortality in patients with…”
BackgroundSGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
Rolek, B., Haber, M., Gajewska, M., Rogula, S., Pietrasik, A., & Gąsecka, A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10080322 · Cited by 65
“The DAPA-HF and EMPEROR-REDUCED trials were designed to assess the efficacy of dapagliflozin and empagliflozin, respectively, in subjects suffering from heart failure with reduced ejection fraction (HFrEF) [30,31].”
MethodSGLT2 inhibitors: Beyond glycemic control
Hasan, I., Rashid, T., Jaikaransingh, V., Heilig, C., Abdel‐Rahman, E. M., & Awad, A. S. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100335 · Cited by 71
“…volume (LVESV), left ventricular (LV) mass (P < 0.001); hazard ratio (HR) of 0.78 (CI:0.64 – 0.97) for time to first event of cardiovascular death (CVD); HR for hospitalization for HF 0.75 (CI:0.65-0.086) & significant decrease in 24 hrs. systolic BP (SBP) and diastolic BP (DBP) [40,45 – 46 , 48].”
BackgroundInfluentialTheofilis, P., Antonopoulos, A. S., Katsimichas, T., Oikonomou, E. K., Siasos, G., Aggeli, C., Tsioufis, K. P., & Tousoulis, D. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106243 · Cited by 62
Pocock, S., Ferreira, J. P., Gregson, J., Anker, S. D., Butler, J., Filippatos, G. S., Gollop, N. D., Iwata, T., Brueckmann, M., Januzzi, J. L., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab579 · Cited by 56
Self-citationMyocardial Oedema: Pathophysiological Basis and Implications for the Failing Heart
Vasques‐Nóvoa, F., Angélico‐Gonçalves, A., Alvarenga, J. M., Nóbrega, J., Cerqueira, R. J., Mâncio, J., Leite-Moreira, A. F., & Roncon‐Albuquerque, R. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13775 · Cited by 62
Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure
Ferreira, J. P., Zannad, F. M., Butler, J., Filippatos, G. S., Pocock, S., Brueckmann, M., Steubl, D., Schueler, E., Anker, S. D., & Packer, M. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.2924 · Cited by 57
“Laboratory values Troponin T, median (IQR), ng/mLf 17 (11-26) 22 (14-33) 28 (18-44) <.”
Self-citationMechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value
Xie, Y., Wei, Y., Li, D., Pu, J., Ding, H., & Zhang, X. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001380 · Cited by 59
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events
Pitt, B., Bhatt, D. L., Szarek, M. J., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.05.026 · Cited by 56
Self-citation2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 109
Farmer, R. E., Beard, I., Raza, S. I., Gollop, N. D., Patel, N., Tebboth, A., McGovern, A. P., Kanumilli, N., & Ternouth, A. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.12.015 · Cited by 55
“More recently, SGLT2 inhibitors have shown further benefits in people with heart failure without diabetes.(31,32) Whether this scenario further increases uptake in the subset of T2DM patients with comorbid heart failure, and also if it encourages prescribers to move away from insulin in patients with a history of CVD,…”
BackgroundNdumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
The role of hyperglycaemia in the development of diabetic cardiomyopathy
Hayek, M. S. E., Ernande, L., Bénitah, J., Gomez, A. M., & Pereira, L. (2021) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2021.08.004 · Cited by 58
“GLP-1 agonists have demonstrated a non-inferiority effect compared with placebo, whereas the new therapeutic class of SGLT2 inhibitors”
BackgroundKatsurada, K., Nandi, S. S., Sharma, N. M., & Patel, K. P. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008365 · Cited by 57
Filippatos, G. S., Anker, S. D., Butler, J., Farmakis, D. T., Ferreira, J. P., Gollop, N. D., Brueckmann, M., Iwata, T., Pocock, S., Zannad, F. M., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2707 · Cited by 58
Self-citationChen, J., Yin, D., & Dou, K. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01875-8 · Cited by 67
Management of Worsening Heart Failure With Reduced Ejection Fraction
Greene, S. J., Bauersachs, J. K., Brugts, J. J., Ezekowitz, J. A., Filippatos, G. S., Gustafsson, F., Lam, C. S. P., Lund, L. H., Mentz, R. J., Pieske, B. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.057 · Cited by 55
Self-citationZhang, H., Ding, L., Mi, L., Zhang, A.-K., Zhang, K., Jiang, Z., Yu, F., Yan, X.-X., Shen, Y.-J., & Tang, M. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad356 · Cited by 54
Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease
Neijenhuis, R. M. L., MacDonald, S. T., Zemrak, F., Mertens, B. J. A., Dinsdale, A., Hunter, A. L., Walker, N. L., Swan, L., Reddy, S., Rotmans, J. I., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.017 · Cited by 57
“9 While significant reductions in NT-proBNP have also been reported in the majority of the large SGLT2i trials, 19,20,22 the risk of HF events is reduced independently of baseline NT-proBNP levels.”
Umapathysivam, M. M., Gunton, J., Stranks, S. N., & Jesudason, D. (2024) · Diabetes Care · doi:10.2337/dc23-1163 · Cited by 57
Anders, H., Peired, A. J., & Romagnani, P. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa329 · Cited by 56
Anker, S. D., Khan, M. S., Butler, J., Ofstad, A. P., Peil, B., Pfarr, E., Doehner, W., Sattar, N. A., Coats, A. J. S., Filippatos, G. S., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2728 · Cited by 60
Self-citationEmpagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis
Radlinger, B., Ress, C., Folie, S., Salzmann, K., Lechuga, A., Weiss, B., Salvenmoser, W., Graber, M., Hirsch, J., Holfeld, J., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05851-x · Cited by 62
“Beside their glucoselowering properties these effects include cardio- and nephroprotection, and a modest reduction in BP and body weight [7, 8].”
BackgroundAbdeldayem, T. K., Younis, O., Zarif, B., Attia, S., & AbdelSalam, A. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.03.002 · Cited by 54
Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus
Zhang, R., Xie, Q., Lu, X., Fan, R., & Tong, N. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01325-9 · Cited by 63
“Specifically, both dapagliflozin and empagliflozin have been shown to decrease the occurrence of HF exacerbations and reduce the risk of CV mortality [19, 27].”
BackgroundRosano, G. M. C., Teerlink, J. R., Kinugawa, K., Bayés‐Genís, A., Chioncel, O. D., Fang, J. C.-T., Greenberg, B., Ibrahim, N. E., Imamura, T., Inomata, T., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3646 · Cited by 60
Zannad, F. M., O’Connor, C. M., Butler, J., McMullan, C. J., Anstrom, K. J., Barash, I., Bonaca, M. P., Borentain, M., Corda, S., Gates, D. F., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01682-4 · Cited by 66
Self-citationPatorno, E., Pawar, A. M., Wexler, D. J., Glynn, R. J., Bessette, L. G., Paik, J. M., Najafzadeh, M., Brodovicz, K. G., Déruaz‐Luyet, A., & Schneeweiß, S. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14593 · Cited by 56
Seferovic, P. M., Polovina, M. M., Adlbrecht, C., Bělohlávek, J., Chioncel, O., Gonçalvesová, E., Milinković, I., Grupper, A., Halmosi, R., Kamzola, G., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2378 · Cited by 59
Self-citationVerma, S., Dhingra, N. K., Butler, J., Anker, S. D., Ferreira, J. P., Filippatos, G., Januzzi, J. L., Lam, C. S. P., Sattar, N. A., Peil, B., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00292-8 · Cited by 53
Self-citationYang, J., Grafton, F., Ranjbarvaziri, S., Budan, A., Farshidfar, F., Cho, M., Xu, E., Ho, J. J., Maddah, M., Loewke, K. E., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl5654 · Cited by 56
Metadata
- Authors
- Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., Jamal, W., Kimura, K., Schnee, J., Zeller, C., Cotton, D., Bocchi, E., Böhm, M., Choi, D.-J., Chopra, V., Chuquiure, E., Giannetti, N., Janssens, S., Zhang, J., Gonzalez Juanatey, J. R., Kaul, S., Brunner-La Rocca, H.-P., Merkely, B., Nicholls, S. J., Perrone, S., Pina, I., Ponikowski, P., Sattar, N., Senni, M., Seronde, M.-F., Spinar, J., Squire, I., Taddei, S., Wanner, C., & Zannad, F.
- Affiliations
- University of Leicester (GB)
- Harvard University (US)
- St. Michael's Hospital (CA)
- Kyushu University (JP)
- Boehringer Ingelheim (Germany) (DE)
- Seoul National University (KR)
- From Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas (M.P.); Imperial College (M.P.) and the Department of Medical Statistics, London School of Hygiene and Tropical Medicine (S.J.P.), London, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow (N.S.), and the Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Biomedical Research Centre, Glenfield Hospital, Leicester (I.S.) — all in the United...
- Cedars-Sinai Medical Center (US)
- University of Pisa (IT)
- ORCID
- Packer, Milton
- Anker, Stefan D.
- Butler, Javed
- Filippatos, Gerasimos
- Pocock, Stuart J.
- Januzzi, James
- Verma, Subodh
- Tsutsui, Hiroyuki
- Brueckmann, Martina
- Jamal, Waheed
- Kimura, Karen
- Schnee, Janet
- Zeller, Cordula
- Cotton, Daniel
- Bocchi, Edimar
- Böhm, Michael
- Choi, Dong-Ju
- Chopra, Vijay
- Giannetti, Nadia
- Janssens, Stefan
- Zhang, Jian
- Kaul, Sanjay
- Nicholls, Stephen J.
- Perrone, Sergio
- Ponikowski, Piotr
- Sattar, Naveed
- Senni, Michele
- Seronde, Marie-France
- Squire, Iain
- Taddei, Stefano
- Wanner, Christoph
- Zannad, Faiez
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-10-08
- Volume
- 383
- Issue
- 15
- Pages
- 1413-1424
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3081830235
- Semantic Scholar
- 9f762448aff37cda38166e57ac40bc13f0005f51
- Cited by
- 5,206
- References
- 10
- Citations by year
- 2026: 638 · 2025: 757 · 2024: 820 · 2023: 965 · 2022: 936 · 2021: 910 · 2020: 163
- FWCI
- 459.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- HAL (submittedVersion, other-oa)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Figshare (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- Boehringer Ingelheim
- Eli Lilly
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- empagliflozin, SGLT2 inhibitors, heart failure with reduced ejection fraction, cardiovascular mortality, hospitalization for worsening heart failure, renal outcomes, estimated glomerular filtration rate decline, genital tract infection, diabetes status, EMPEROR-Reduced trial
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Benzhydryl Compounds, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glomerular Filtration Rate, Glucosides, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Stroke Volume, Proportional Hazards Models, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
